AUTHOR=Ren Bolin , Ren Xiaolei , Wang Lu , Tu Chao , Zhang Wenchao , Liu Zhongyue , Qi Lin , Wan Lu , Pang Ke , Tao Cheng , Li Zhihong 

TITLE=A bibliometric research based on hotspots and frontier trends of denosumab

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.929223

DOI=10.3389/fphar.2022.929223

ISSN=1663-9812

ABSTRACT=Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor RANKL. It has been widely used in the treatment of osteoporosis and giant cell tumor of bone, and the prevention of malignant SREs. We collected the research results and related MeSH terms of Denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustering by Bibliographic Co-Occurrence Analysis System (BICOMB) and Graph Clustering Toolkit (gCLUTO). The results show that the number of Denosumab-related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc being the most influential in the past 10 years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, YUKIO NAKAMURA, TAKAKO SUZUKI, and HIROYUKI KATO joined the field relatively late but produced the most. The clinical comparison and combination of Denosumab with other drugs in the treatment of osteoporosis was the biggest focus of research. Drug withdrawal rebound and management strategies had gained more attention and controversy in recent years. MeSH analysis revealed 8 major categories of research hotspots. Among them, exploring the multiple roles of RANK-RANKL-OPG system in tumor progression，metastasis and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for spinal internal fixation and orthopedic prothesis implantation. Taken together, the advantages of Denosumab were broad and cost-effective, but there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures etc., which need to be solved properly.